Stockscreener 앱 받기
0.00
100.00%
-0.10
시간 외 거래:
.02
0.02
+
Telesis Bio Inc 주식(TBIO)의 최신 뉴스
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Global mRNA Synthesis and Manufacturing Market to Increase at a Steady Growth Rate of ~4% by 2032 | DelveInsight - GlobeNewswire
Telesis Bio Inks Regeneron Deal - San Diego Business Journal
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results - Insider Monkey
Regeneron to deploy Telesis Bio’s Gibson SOLA at R&D facilities - Yahoo Finance
Regeneron partners with Telesis Bio for swift on-site gene synthesis - World Pharmaceutical Frontiers
Telesis Bio and Regeneron Partner on Gene Synthesis - Technology Networks
Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency - Insider Monkey
Regeneron (REGN) Adopts Telesis Bio's Gene Synthesis Platform | - GuruFocus
Regeneron Pharmaceuticals (NasdaqGS:REGN) Adopts Innovative Technology for Faster Drug Discovery - Yahoo Finance
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis - BioSpace
TBIOTRANSLATE BIO, INC. Latest Stock News & Market Updates - Stock Titan
Driving Synthetic Biology Forward Through Adoption of Technology Enabling Rapid DNA and mRNA Synthesis - MedCity News
What is going on with the stock tbio - AInvest
Telesis Bio (NASDAQ:TBIO) Stock Price Up 28.9% – Here’s Why - American Banking and Market News
Telesis Bio (NASDAQ:TBIO) Trading Up 28.9% – Still a Buy? - Defense World
Telesis Bio Bullish on Future After Whirlwind Year - San Diego Business Journal
TELESIS BIO INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
FT ranking: The Americas’ Fastest-Growing Companies 2025 - Financial Times
Telesis Bio (NASDAQ:TBIO) Trading Down 23.1% – Here’s Why - Defense World
$21M Investment Powers Telesis Bio's Game-Changing Overnight DNA Synthesis Technology - StockTitan
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis - Yahoo Finance
Telesis Bio (NASDAQ:TBIO) Trading 27.3% Higher – Should You Buy? - Defense World
Financial Contrast: Telesis Bio (NASDAQ:TBIO) and Prenetics Global (NASDAQ:PRE) - Defense World
Nuclera appoints William J. Kullback as Non-Executive Director - Cambridge Network
Carver Bancorp Leads 3 Noteworthy US Penny Stocks - simplywall.st
Telesis Bio Inc. Faces Financial Challenges Amidst Revenue Decline - TipRanks
Telesis Bio's Chief Legal Officer To Leave Post This Week - Law360
One new option listing and ten option delistings on October 21st - TipRanks
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62% - MSN
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - MSN
Telesis Bio Stock Skyrockets after Beckman Coulter Partnership - timothysykes.com
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis - Yahoo Finance
Is Telesis Bio Inc. on the Brink of a Major Breakthrough? - timothysykes.com
Codex DNA stock plunges to 52-week low of $1.65 - Investing.com
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market | TBIO Stock News - Stock Titan
Telesis Bio completes sale of subsidiary EtonBio - Investing.com
Enzymatic DNA Synthesis Market Size | Industry Report 2033 - Grand View Research
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results - Yahoo Finance
DNA Synthesis Market Size, Share | Growth Report [2025-2032] - Fortune Business Insights
Telesis Bio Reports First Quarter 2024 Financial Results - Yahoo Finance
Telesis Bio Announces Reverse Stock Split - Yahoo Finance
Telesis Bio appoints new CEO as founder steps down - Investing.com
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results - Koreabizwire
Press Release Service: Enzymatic DNA Synthesis Market to Surge to US$2.11 Billion by 2028 Driven by Advances in Synthetic Biology and Genetic Engineering TechnologiesResearchAndMarkets.com - CRISPR Medicine News
New research finds that despite the stereotypes, women actually negotiate their salaries more than men - Fortune
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023, Business Wires News - AsiaOne
Enzymatic DNA Synthesis Market 2022: Explore Top Factors that Will Boost the Global Market by 2028 - openPR.com
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit - Technology Networks
Telesis Bio to Present at Jefferies Healthcare Conference 2023 - Koreabizwire
Sidley Represents Northpond Ventures in Its PIPE Investment in Telesis Bio Inc. - Sidley Austin LLP
Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock - The Globe and Mail
Telesis Bio to Present at SynBioBeta 2023 - Koreabizwire
Blue Bird, First Solar rise; Harrow Health, Telesis Bio fall - Daily Sentinel Star
Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up - Stock Titan
Telesis Bio Releases BioXp® Select mRNA Synthesis Kit To Expand the Utility, Speed and Impact of Its Automated Synthetic Biology Workstation - Technology Networks
Telesis Bio, Inc. (NASDAQ:TBIO) Q4 2022 Earnings Call Transcript - Insider Monkey
Synthetic Biology Startup Molecular Assemblies Ships First DNA From New San Diego Facility - Forbes
Enzymatic DNA Synthesis Market Worth $2.24 Billion, by 2028 - GlobeNewswire
Automating DNA Synthesis Boosts Drug Discovery: - Mary Ann Liebert, Inc.
Global Cloning And Mutagenesis Market Size Report, 2030 - Grand View Research
Codex DNA to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 - Stock Titan
Codex DNA to Present at the 2022 Jefferies Healthcare Conference - Stock Titan
0.86%
0.67%
자본화:
|
볼륨(24시간):